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Background: Diabetes mellitus (DM) and osteoporosis are two frequent medical conditions with 
an increasing prevalence in elderly people and are responsible for large number of incurable 
fractures. This study is designed experimentally in female rats in order to determine whether 
combined treatment of insulin and parathyroid hormone (PTH) enhances the reversibility of 
the osteoporotic changes that occurred in streptozotocin (STZ)-induced DM. 
Materials and methods: In this study, 30 adult female rats aged 3 months were used, they were 
randomly divided into: control group (6 rats) and diabetes group (24 rats), in which experimental DM 
was induced by i.p. injection of a single dose of STZ (60 mg/kg/body weight). Diabetic group was 
further divided into four subgroups (6 rats each): non-treated diabetic, insulin-treated (8–12 units 
s.c./day of Humalin U-40), PTH-treated (6.0 μg s.c./kg/day) and combined insulin and PTH-treated 
subgroups. All tested groups were assessed for body weight, food and water consumptions. 
Results: At the end of the experimental period, the bone mineral density (BMD) was measured 
for all rats of different groups; then the rats were sacrificed and blood samples were collected for 
measuring glucose, alkaline phosphatase and osteocalcin levels. Right femora were dissected out 
and subjected to measurement of diameter of neck and shaft, length of shaft, and weight. Then 
the femora specimens were processed and stained with haematoxylin and eosin for histological 
study. The results showed that there was a statistically significant, decrease in BMD, increase 
in the level of alkaline phosphate, and decrease in the level of osteocalcin in rats in diabetic 
group compared with other groups; these parameters improved in other groups, especially in 
diabetes/insulin/PTH group. The rats in diabetic group showed statistically significant decrease in 
neck and shaft diameters and weight of femur bone compared with other groups, while rats in 
diabetes/insulin/PTH group showed a significant improvement of these parameters. In diabetic 
group, there were different histopathological changes in cortical bone and Haversian canals, 
which improved in other groups, especially in rats in diabetes/insulin/PTH group. 
Conclusions: The untreated DM resulted in dramatic reduction in BMD and morphometric 
parameters. Treatment with insulin ameliorated these effects to some extent, while PTH co-
-treatment had a more positive effect. The combination of PTH and insulin resulted in stronger 
improvement of all parameters to approximately like those of control rats. (Folia Morphol 
2016; 75, 3: 341–354)
Key words: diabetes mellitus, osteoporosis, insulin, parathormone
Address for correspondence: M.M.O. El-Fark, MSc, MD, Assistant Professor of Anatomy and Embryology, College of Medicine, King Abdul Aziz 
University (KAU), Jeddah, P.O. Box: 80205 Jeddah 21589, Saudi Arabia, e-mail: anatomist1996@yahoo.com 
342
Folia Morphol., 2016, Vol. 75, No. 3
INTRODUCTION
Osteoporosis is a main bone complication in pa-
tients with diabetes mellitus (DM) [9, 25]. Clinically 
speaking, it is well established that osteoporosis and 
DM are prevalent diseases with significant association 
of morbidity and mortality that represent very impera-
tive public health concerns. Patients with DM have 
an increased risk of bone fractures [26]. Recognition 
of at-risk patients is critical in both prevention and 
treatment of osteoporosis. All diabetes-related fac-
tors should be considered in assessing osteoporosis 
and fracture risk reduction should be recommended 
to diabetic patients. Many agents are available for 
the prevention and treatment of osteoporosis in the 
diabetic population [26]. 
Diabetes mellitus is a pandemic debilitating meta-
bolic disease that poses serious problems to health, 
community resources and socioeconomic services 
due to its dramatic increase [3, 48]. The increased 
incidence of DM could be attributed to longer life 
expectancy associated with minimal physical activity 
and increased intake of high energy food [22, 47]. 
The World Health Organisation report in 2009 esti-
mated that more than 180 million people with DM 
are present worldwide, and are expected to be more 
than double by 2030 [60, 61].
Diabetes mellitus is a complex disorder producing 
functional impairment in multiple organ systems 
[3, 48]. Besides to its well-known complications such 
as retinopathy, nephropathy, neuropathy and arterio-
sclerosis, it could cause also many bone complications 
[10, 11, 32]. It is well recognised that the diabetic 
patients have various skeletal disorders, including de-
creased bone density (osteopoenia), which might be 
due to a deficit in bone formation [33, 34], decreased 
bone volume [6], alterations in calcium, phosphate 
and bone metabolism [46], increased fracture rates 
[28, 48], and delayed fracture healing [42]. 
Understanding the mechanism of diabetic bone 
loss is essential to determine the best therapy. In the 
majority of cases, osteoporosis in DM is treated the 
same as osteoporosis in subjects without diabetes 
[37]. Osteoporotic medications are mainly divided 
into two categories: antiresorptive medications and 
bone-forming (anabolic) medications [57]. Antire-
sorptive drugs e.g. bisphosphonates (alendronate, 
ibandronate and risedronate) are clinically used to 
treat osteoporotic spine and hip fractures [10]. Bis-
phosphonates are indicated for prevention as well as 
treatment of osteoporosis in diabetic postmenopau-
sal women [24]. However, some reports suggested 
that DM may be a risk factor for bisphosphonate-
related osteonecrosis and therefore, that patients 
with DM being treated with bisphosphonates should 
be carefully monitored [31].  
Currently, the only anabolic treatment approved 
for use in developed countries is the parathyroid hor-
mone (PTH) [59]. Intermittent administration of PTH 
has been shown to have a potent anabolic effect on 
bone in various animal models and humans [2]. PTH 
can increase bone mass in osteoporotic humans and 
rats with osteopoenia induced by various causes [30, 
55, 56]. Several studies have reported that intermittent 
administration of human PTH also enhances fracture 
healing of cortical bones such as shaft of femur or tibia 
after surgical intervention in animals [4, 41], even in 
an osteoporotic animal model [27]. Therefore, PTH is 
the only one candidate for the treatment of diabetes-
induced osteoporosis [55]. 
Furthermore, it was reported that insulin has an 
anabolic effect on cartilage and bone [53], regardless 
of whether the primary effect of insulin is to reverse 
hyperglycaemia or whether there are direct effects 
of insulin on cells [7, 15]. Also, other studies have 
shown that insulin treatment normalised the cellular 
proliferation, chondrogenesis, mineralisation and me-
chanical strength of diabetic fracture healing [7, 16]. 
Therefore, it was expected that the combination of 
insulin and PTH would be more effective than each alone 
in the treatment of diabetic osteoporosis. Consequently, 
the aim of this study was to evaluate the beneficial 
effect of combined insulin and PTH treatment on the 
recovery of the osteoporotic changes that occurred in 
streptozotocin (STZ)-induced diabetes in rats. 
MATERIALS AND METHODS
Experimental design and animal grouping
Thirty adult female Sprague-Dawley rats were used 
in this study. The rats were 3-month-old and body 
weight ranged 200–250 g. They were purchased from 
the animal house of King Fahd Research Centre and 
were housed in large plastic cages under the normal 
laboratory conditions, environmentally controlled (25o, 
12-h light/12-h dark cycles). The rats were fed a com-
mercial standard diet. Food and water were freely avail-
able. All experimental protocols were approved by the 
Unit of Biomedical Ethics Research Committee, Faculty 
of Medicine, King Abdulaziz University [(HA-02-J-008) 
No. of registration at National Committee of Bio. & 
Med. Ethics]. In addition, the animals were adapted to 
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the environment for 1 week before starting the experi-
ment and then they were randomly divided into the 
following groups.
Control group (6 rats) — in which the rats were 
injected intraperitoneally with normal saline (0.9% 
NaCl solution) in equivalent amounts to that of the 
treated groups.
Diabetic group (24 rats) — in which the rats 
were rendered diabetic. DM was induced by an in-
traperitoneal (i.p.) injection of a single dose of STZ 
(60 mg/kg body weight) after 18 h fasting [35]. STZ was 
dissolved in 0.1 M citrate buffer (pH 4.5) immediately 
before use. Seventy-two hours following the injection, 
tail blood samples was obtained for measuring blood 
glucose concentration by using glucometer (Smart-
DC, Germany). Animals were classified as diabetics 
when glycaemia exceed 300 mg/dL [51]. All hormonal 
treatments were started 2 months after induction of 
DM by STZ injection, and then the rats were divided 
into four subgroups (6 rats each) as follows:
—  Diabetes group — in which the diabetic rats were 
left without any treatment;
—  Diabetes/insulin group — in which the diabetic 
rats were given insulin subcutaneously (Humalin 
U-40) at a dose of 8–12 units per day, daily for 
2 months. The dose of insulin was adjusted to 
blood glucose level every 2 days [51];
—  Diabetes/PTH group — in which the diabetic 
rats were given PTH (dissolved in 0.1 M sodium 
acetate buffer, pH 7.2) subcutaneously at a dose 
6.0 μg/kg per day for 2 months. The dose of PTH 
was based on previous studies, which showed 
that treatment with low-dose PTH (6.0 μg/kg/day) 
exerted anabolic effects on bone formation and 
bone mass [55];
—  Diabetes/insulin/PTH group — in which the dia-
betic rats were given PTH and insulin together in 
the same doses as above. 
Both food (g) and water (mL) consumptions of 
rats were measured daily. Body weight (g) of the rats 
was measured at the beginning of the study (initial 
body weight) and at the end of the study (final body 
weight), and then the body weight difference (final– 
–initial weight) was calculated. 
Drugs and hormones
All chemicals, drugs and hormones used in this 
study were purchased through local scientific agents, 
Jeddah, KSA. STZ [(N-(methylonitrosocarbamoilo) D-
glucosamine) (Sigma, Chemical Company, St. Louis, 
USA)], insulin hormone [Insulin solution, Sigma, 
Chemical Company, St. Louis, USA] and parathyroid 
hormone fragment 1-34 human [Sigma, Chemical 
Company, St. Louis, USA]. 
Methods
At the end of the experiment, the following tech-
niques were adopted:
Bone mineral density (BMD). BMD was meas-
ured in both femur and tibia (right and left sides) for 
all rats of the different experimental groups under 
anaesthetisation with i.p. injection of 4 mL of mixture 
3:1 (ketamine 3 mg/kg and seton 1 mg/kg) [39]. The 
measurement was done by dual-energy X-ray ab-
sorptiometry (DEXA) using a LUNAR Prodigy Model, 
SA1002XR01, General electric, Madison, WI, USA, in 
the Centre of Excellence for Osteoporosis Research 
(CEOR), KAU, Jeddah, KSA adapted for measurements 
of small animals. 
Biochemical analysis. The rats were sacrificed, 
blood was collected by cardiac puncture and blood 
samples were centrifuged at 3000 rpm for 15 min. 
The samples were divided into aliquots; plasma on 
sodium fluoride for glucose assessment which would 
be measured immediately and sera were used for all 
other parameters (serum alkaline phosphatase and 
osteocalcin); all parameters were measured by the 
commercially available kits. Sera were stored at –80°C 
until assayed.
Bone morphometric study. The femora of rats of 
different groups were dissected out from the sacri-
ficed animals. The following morphometric measure-
ments were taken: diameter of the median points of 
the femur neck, diameter of the shaft of the femur, 
length of the shaft of the femur, and femur weight. 
All the measurements were obtained by the same 
experimenter, using a millimetre metallic ruler and 
a “Vernier Calibre”. The measurements represented 
the arithmetic mean of three repetitions for each 
parameter analysed.
Bone histopathological procedures. The femora 
were cut distally, 5 mm proximally to the medial con-
dyle articular surface. The cut specimens were placed 
in neutral buffered formalin solution for 48 h, deminer-
alised in 7.5% ethylene diaminetetraacetic acid (EDTA) 
in 0.1 mol/L cacodylate buffer over 1 week, rinsed in 
buffer, and then stored in 70% ethanol. They were 
then dehydrated through a graded series of ethanol 
and acetone and embedded in paraffin wax. 5 μm thick 
frontal sections were cut from femurs, using a rotatory 
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microtome (Leica pharmaceutical company, Germany), 
and mounted on glass slides. Sections were stained with 
haematoxylin and eosin for routine histological study. 
Statistical analysis
Statistical analyses were performed by using SPSS 
program version 16 (IBM-USA). One way-analysis of vari-
ance (ANOVA) with Bonferroni post hoc test was carried 
out. Data were presented as mean ± standard deviation 
(SD). P < 0.05 was considered statistically significant.
RESULTS
Body weight changes, food and water consumption
As shown in Table 1, there was a considerable 
increase in body weight after 2 months in control 
group (21.29%), while rats in both diabetes and dia-
betes/PTH groups showed a statistically significant 
reduction of body weight, compared with the other 
study groups, at the end of the study (6% in diabetes 
group and 5.76% in diabetes/PTH group). However, 
administration of insulin resulted in an increase in 
body weight gain in rats in both diabetes/insulin and 
diabetes/insulin/PTH treated groups (9% and 8.8%, 
respectively), with a statistically significant reduction 
compared with the control group. Also, food and 
water consumptions were increased in rats in both 
diabetes and diabetes/PTH groups with a statistically 
significantly difference when compared with the oth-
er study groups; however, administration of insulin 
in both diabetes/insulin, and diabetes/insulin/PTH re-
sulted in a reduction of food and water consumption 
to be approximated to that in control group. 
Bone mineral density
The BMD of the lower limbs was the highest in 
control group, followed by diabetes/insulin/PTH, dia-
betes/PTH, diabetes/insulin groups, and finally it was 
the lowest in diabetes group. There was a statistically 
significant decrease in BMD in rats in diabetes group 
when compared with control diabetes/PTH and diabe-
tes/insulin/PTH groups. Rats from diabetes/PTH group 
showed a statistically significant decrease in BMD 
when compared with controls. Also, rats from dia-
betes/insulin group showed a statistically significant 
decrease in BMD when compared with both control 
and diabetes/insulin/PTH groups (Table 2).  
Biochemical results
Diabetic rats in both diabetes and diabetes/PTH 
treated groups showed a statistically significant 
marked hyperglycaemia when compared with the 
control, diabetes/insulin, and diabetes/insulin/PTH 
treated groups (Table 3). 
Regarding the level of serum alkaline phosphatase, 
it was in the normal range in the control group, while 
it was elevated in diabetes group and it was elevated 
to some extent in the other groups (diabetes/insulin, 
diabetes/PTH and diabetes/insulin/PTH). There was 
a statistically significant increase in the level of alkaline 
phosphate in rats in diabetic group when compared 
Table 1. Body weight changes, food and water consumption
Parameters Control Diabetes Diabetes/insulin Diabetes/PTH Diabetes/insulin/  
/PTH
Initial body weight [g] 245.2 ± 4.5 247.4 ± 3.7 243.2 ± 4.8 244.7 ± 3.8 242.8 ± 4.2
Final body weight [g] 297.4 ± 8.9 232.5 ± 4.2c,g,h 265.1 ± 7.6b 230.6 ± 4.6c,g,h 264.3 ± 6.9b
Body weight difference 52.2 ± 4.4 –14.9 ± 0.9 d 21.9 ± 2.8 c –14.1 ± 0.8d 21.5 ± 2.7 c
Food consumption  [g/day] 24.5 ± 5.2 42.8 ± 9.6 a 29.8 ± 6.7 42.3 ± 9.8a 30.2 ± 7.1
Water consumption [mL/day] 30.2 ± 7.1 89.4 ± 12.6c,e,f 39.6 ± 9.3 90.1 ± 11.9c,,e,f 39.9 ± 9.8
Results are expressed as mean ± standard deviation; n = 6. Significance of differences between groups was evaluated by one-way ANOVA followed by Bonferroni post-hoc test;  
a — p < 0.05 vs. control group; b — p < 0.01 vs. control group; c — p < 0.001 vs. control group; d — p < 0.0001 vs. control group; e — p < 0.01 vs. diabetes/insulin group;  
f — p < 0.01 vs. diabetes/insulin/PTH group; g — p < 0.0001 vs. diabetes/insulin group; h — p < 0.0001 vs. diabetes/insulin/PTH group
Table 2. Bone mineral density (BMD)
Parameters Control Diabetes Diabetes/insulin Diabetes/PTH Diabetes/insulin/  
/PTH
BMD [mg/cm2] 0.086 ± 0.004 0.074 ± 0.004b,d,e 0.078 ± 0.004b,c 0.081 ± 0.003a 0.084 ± 0.004
Results are expressed as mean ± standard deviation, n = 12. Significance of differences between groups was evaluated by one-way ANOVA followed by Bonferroni post-hoc test;  
a — p < 0.05 vs. control group; b — p < 0.0001 vs. control group; c — p < 0.01 vs. diabetes/insulin/PTH group; d — p < 0.0001 vs. diabetes/insulin/PTH group; e — p < 0.01 vs. diabetes/PTH group
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with control, diabetes/PTH, and diabetes/insulin/PTH 
groups. Rats from diabetes/PTH group showed a statis-
tically significant increase in alkaline phosphate when 
compared with controls. Also, rats from diabetes/insu-
lin group showed a statistically significant increase in 
alkaline phosphate when compared with both control 
and diabetes/insulin/PTH groups (Table 3). 
Regarding the level of serum osteocalcin, it was 
observed that this level was decreased to a large 
extent in untreated rats in diabetes group to be 
only 29.4% of that in control group. This decrease 
was also observed to a less extent in the other 
groups to be 74.6%, 83.6%, and 91.2% in dia-
betes/insulin, diabetes/PTH, and diabetes/insulin/
PTH groups, respectively, of that in control group. 
When compared with control group, there was 
a statistically significant decrease in the level of os-
teocalcin in the other four groups. Rats in diabetes, 
diabetes/insulin, and diabetes/PTH groups showed 
a statistically significant decrease when compared 
with diabetes/insulin/PTH group. Also, there was 
a statistically significant decrease in both diabetes 
and diabetes/insulin groups when compared with 
diabetes/PTH group, and in diabetes/insulin group 
when compared with diabetes/PTH group (Table 3).
Morphometric parameters
Morphometric analysis was carried out through 
measuring shaft diameter, neck diameter, shaft length 
and dry weight of the femur bone. The rats in dia-
betes group revealed the lowest measurements for 
shaft diameter and neck diameter, with a statisti-
cally significant decrease in the shaft diameter when 
compared with both control and diabetes/insulin/
PTH groups. At the same time, there was a statisti-
cally significant decrease in the neck diameter when 
compared with control, diabetes/PTH, and diabetes/
insulin/PTH groups. Rats from both diabetes/insulin 
and diabetes/PTH groups showed a statistically signifi-
cant decrease in the diameter of both shaft and neck 
of femur bone. Regarding the length of femur bone 
shaft, the length varied, but there were no significant 
differences between all study groups (Table 4). 
The femur weight was reduced in diabetes/insu-
lin/PTH, diabetes/PTH, diabetes/insulin and diabetes 
groups. There was a statistically significant decrease 
in the femur weight in the diabetes group when 
compared with control, diabetes/PTH, and diabetes/
insulin/PTH groups. Also, there was a statistically sig-
nificant decrease in the femur weight in both diabe-
tes/insulin and diabetes/PTH groups when compared 
with control group (Table 4). 
Histological results
Microscopic examination of the bone sections 
from control groups (Fig. 1) showed normal bone 
architecture of outer cortical bone and inner spongy 
bone. The cortical bone was covered by periosteum 
Table 3. Biochemical parameters
Parameters Control Diabetes Diabetes/insulin Diabetes/PTH Diabetes/insulin/ 
/PTH
Glucose [mg/dL] 122.4 ± 21.9 485.9 ± 44.5b,d,g 131.4 ± 24.5 483.6 ± 45.8b,d,g 132.7 ± 26.3
Serum alkaline phosphatase 
[U/L]
295.17 ± 11.69 329.58 ± 14.35b,d,e 318.17 ± 13.52 b,c 311.92 ± 12.7a 301.58 ± 10.87
Serum osteocalcin [ng/mL] 3.54 ± 0.04 1.04 ± 0.05b,d,f,g 2.64 ± 0.06 b,d,f 2.96 ± 0.07b,d 3.23 ± 0.07b
Results are expressed as mean ± standard deviation, n = 6. Significance of differences between groups was evaluated by one-way ANOVA followed by Bonferroni post-hoc test;  
a — p < 0.05 vs. control group; b — p < 0.0001 vs. control group; c — p < 0.05 vs. diabetes/insulin /PTH group; d — p < 0.0001 vs. diabetes/insulin /PTH group; e — p < 0.05 vs. diabetes/ 
/PTH group; f — p < 0.0001 vs. diabetes/PTH group; g — p < 0.0001 vs. diabetes/insulin group
Table 4. Morphometric parameters
Femur bone Control Diabetes Diabetes/insulin Diabetes/PTH Diabetes/insulin/ 
/PTH
Shaft diameter [mm] 4.25 ± 0.16 3.87 ± 0.14b,c 3.97 ± 0.14b 4.03 ± 0.15a 4.11 ± 0.15
Neck diameter [mm] 3.60 ± 0.14 3.19 ± 0.13b,d,e 3.29 ± 0.13b 3.37 ± 0.13a 3.45 ± 0.14
Shaft length [mm] 36.50 ± 1.69 35.45± 1.36 35.85 ± 1.26 36.06 ± 1.35 36.31 ± 1.42
Femur weight [mg] 502.08 ± 17.62 440.67 ± 13.44b,d,e 455.17 ± 13.52b 461.18 ± 13.71b 490.09 ± 16.68
Results are expressed as mean ± standard deviation, n = 12. Significance of differences between groups was evaluated by one-way ANOVA followed by Bonferroni post-hoc test;  
a — p < 0.01 vs. control group; b — p < 0.0001 vs. control group; c — p < 0.01 vs. diabetes/insulin /PTH group; d — p < 0.0001 vs. diabetes/insulin/PTH group; e — p < 0.05 vs. diabetes/ 
/PTH group; PTH — parathyroid hormone
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from outside and by endosteum from inside. The 
periosteum was formed of outer fibrous layer and 
inner osteogenic layer of densely packed osteopro-
genitor and osteoblast cells. The cortical bone showed 
subperiosteal bone deposition appearing as a dis-
tinct basophilic area demarcating the border between 
newly added bone matrix and the older bone 
(Fig. 1A, B). The endosteal surface of the cortical bone 
appeared smooth and was lined with osteoprogeni-
tor and osteoblastic cells with osteoclasts residing in 
their Howship’s lacunae (Fig. 1C). The cortical bone 
tissue was formed of outer circumferential lamellae, 
concentric lamellae around Haversian canals and in-
terstitial lamellae in between them. Osteocytes with 
their darkly stained oval nuclei residing inside their 
lacunae were seen in and between different lamellae 
(Fig. 1D). Higher magnification showed normal sized 
Haversian canals and regular arrangement of the la-
mellae of the matrix (Fig. 1E). The inner spongy bone 
consisted of a network of bony trabeculae separated 
by interconnecting spaces containing bone marrow 
containing developing marrow cells, blood vessels 
and few fat cells. The bone trabeculae consisted of 
irregular bone lamellae of basophilic stainability and 
osteocytes within their lacunae in between bone 
lamellae (Fig. 1F). 
Figure 1. A–F. Photomicrographs of different sections of the distal femur diaphysis from control rats showing outer cortical bone 
(CB) with normal cavity appearance and osteocytes (Os) inside their lacunae. The bone is covered from outside by the periosteum 
(Pr), which shows both an outer fibrous layer (f) and an inner osteogenic layer (o), and from inside by smooth endosteal surface (En). 
Notice subperiosteal bone deposition appearing as distinct basophilic cement line (arrow). The cortical bone tissue is well organised, 
showing outer circumferential lamellae (ol) arranged around the Haversian canals (HC). Also, Volkmann’s canals (VC) are observed. 
Spongy bone is composed of a network of bony trabeculae (T) separated by interconnecting spaces containing bone marrow (BM); 
haematoxylin and eosin; × 100: A, F; × 400: B, C, D; × 600: E.
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In diabetic rats, the microscopic examination 
showed many histopathological changes when com-
pared with that of control group. In some sections, 
thinning of the cortical bone with presence of bony 
grooves and tunnels and formation of multiple cavi-
ties were seen (Fig. 2A, B). In other sections, there 
was apparent hypertrophy of both layers of perios-
teum with flattened osteoprogenitor and rounded 
osteoblasts also forming grooves and tunnels in-
side compact bone (Fig. 2C). The endosteum had 
irregular surface with multiple notches and showed 
an increase in number of osteoclasts and decreased 
lining osteoblasts (Fig. 2D). The Haversian canals ap-
peared shrunken with irregular outlines and forming 
gaps within the bone tissue. Most of osteocytes ap-
peared degenerated with pyknotic nuclei. There were 
some empty lacunae devoid of cells and multiple 
osteoporotic cavities of different sizes (Fig. 2E). The 
inner spongy bone trabeculae showed loss of their 
normal architecture with widening of the intercon-
necting bone marrow spaces. Cavities also appeared 
in bone trabeculae near the medullary cavity, which 
was mostly occupied by fat cells (Fig. 2F). 
In the diabetic rats treated with insulin alone, 
the examination showed slight improvement in os-
teoporotic changes. There was a relative increase 
in the thickness of cortical bone with some small 
osteoporotic cavities and some cement lines indi-
cating bone repair. Outer and inner bone surfaces 
appeared slightly irregular (Fig. 3A, B). Bone matrix 
Figure 2. A–F. Photomicrographs of different sections of the distal femur diaphysis from diabetic rats showing thinning of the cortical bone 
(CB) with no signs of subperiosteal new bone deposition, multiple cavity formation (C), resorption cavities (*). Notice thick and irregular peri-
osteum (Pr), irregular endosteal surface (En) with multiple eroded areas (**). Irregular Haversian systems with irregular lamellae (arrow) and 
many empty lacunae (arrowhead) around Haversian canal (HC). Spongy bone shows decreased number, size, and density of trabeculae (T); 
BM — bone marrow; haematoxylin and eosin; × 100: A, C; × 200: B, F; × 400: D; × 600: E.
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presented areas of deep stainability starting from the 
endosteal bone surface. There were dilated cavities 
with central vascular core. These cavities were seen to 
be surrounded by clear deeply stained cement lines 
(Fig. 3C). The Haversian systems showed irregular 
organisation, with irregular concentric bone lamellae 
around apparently normal Haversian canals (Fig. 3D). 
Moreover, the inner spongy bone presented slight 
widening in the interconnecting bone marrow spaces, 
which contained scattered fat cells. The spongy bone 
trabeculae presented distinct deep basophilic cement 
lines and areas in the core of the trabeculae (Fig. 3E). 
In the diabetic rats treated with PTH alone, the 
examination showed better improvement of oste-
oporotic changes. There was an increase in the thick-
ness of cortical bone with few small osteoporotic 
cavities and some distinct basophilic cement lines 
indicating bone repair. Outer and inner bone surfaces 
appeared more or less regular (Fig. 4A, B). The cortical 
bone contained osteocytes within their lacunae and 
many blood vessels (Fig. 4C). Higher magnification 
displayed adjacent Haversian systems, which were 
normal in size and shape and with normally appear-
ing concentric lamellae and osteocytes (Fig. 4D). In 
addition, in the inner spongy bone, many branching 
and anastomosing bony trabeculae containing osteo-
cytes in their lacunae were observed arising from the 
cortical bone (Fig. 4E). 
In the diabetic rats treated with both insulin and 
PTH, the examination showed a nearly complete re-
Figure 3. A–E. Photomicrographs of different sections of the distal femur diaphysis from diabetic rats treated with insulin showing the cortical  
bone (CB) relatively increased in thickness to be comparable with the controls with the appearance of many small cavities. The outer and 
inner bone surfaces appeared slightly irregular. Notice the regularly arranged bone lamellae (Bl), underneath the periosteum (Pr) and around 
apparently normal Haversian canals (HC). Both layers of periosteum were increased with the appearance of many blood vessels (BV). Spongy 
bone appears with nearly normal trabeculae (T) with less apparent widening in the interconnecting bone marrow spaces; BM — bone marrow;  
En — endosteum; haematoxylin and eosin; × 100: E; × 200: A, B, C; × 600: D.
349
G.S. Abd El Aziz et al., Insulin and parathyroid hormones and induced diabetic osteoporosis
Figure 4. A–E. Photomicrographs of different sections of the distal femur diaphysis from diabetic rats treated with parathyroid hormone showing rela-
tive thickening of the cortical bone (CB) with less bony grooves and more cavities (C). The Haversian systems (HC) are normal in size and shape and 
with normally appearing concentric lamellae. Spongy bone appears with nearly normal trabeculae (T) with less apparent widening in the interconnect-
ing bone marrow spaces; Pr — periosteum; En — endosteum; BM — bone marrow; haematoxylin and eosin; × 200: A, B, C, E; × 600: D. 
versibility of the osteoporotic changes, where there 
was increased thickness of the outer cortical bone to 
be comparable to the control femurs with the appear-
ance of less bony tunnels containing osteoprogenitor 
cells and osteoblast. Also, subperiosteal bone deposi-
tion showing a distinct basophilic cement line was 
seen (Fig. 5A, B). Also, there was a relative increase 
in the thickness of the inner osteogenic layer of the 
periosteum with the appearance of many rounded 
nuclei of osteoblasts. The endosteum had smooth 
surface and was lined with osteoprogenitor cells 
and osteoblasts (Fig. 5C). The cortical bone showed 
concentric bone lamellae around apparently normal 
Haversian canals (Fig. 5D). The inner spongy bone was 
resuming nearly normal thickness and architecture 
with less apparent widening in the interconnecting 
bone marrow spaces. The bone trabeculae presented 
distinct deep basophilic cement lines and areas in the 
core of the trabeculae (Fig. 5E).
DISCUSSION
The relationship between DM and osteoporosis is 
complex. DM causes osteopoenia and hinders frac-
ture healing [42]. The impaired bone formation was 
evidenced by a decrease in both BMD and markers 
of bone formation as serum levels of osteocalcin and 
alkaline phosphatase [8, 21]. Several mechanisms 
have been proposed: changes in cell signalling, in cir-
culating growth factors and in endocrine hormones; 
an increase in the inflammatory process, oxidative 
stress or cell death [37]. It was suggested that dur-
ing growth DM can lead to decrease in bone forma-
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tion, while later in life it leads to an increase in bone 
resorption and osteopoenia. It is thus confirmed in 
many studies that DM can contribute to osteopoenia 
by increasing osteoclast formation [52]. 
In the present study, following induction of dia-
betes, animals displayed the expected symptoms of 
insulin-dependent DM, i.e., hyperglycaemia, polydip-
sia, depression of body mass gain, and the increase 
in food and water intake. Administration of insulin 
to diabetic rats caused a reduction in food and water 
intake and an increase in the body weight gain. These 
data were in agreement with those reported by Havel 
et al. [20] and Akbarzadeh et al. [1]. 
In the present study, the diabetic rats revealed 
a decreased BMD and several bone changes which 
indicated the process of osteoporosis. The existing 
relation between BMD, the metabolism in patients 
with DM and osteoporosis is still in controversy. Some 
studies revealed no significant difference in BMD 
values at the hip region between diabetic and nor-
mal control women [49]. Others reported low bone 
density in type 2 diabetic patients [34].
The biochemical results in this study showed that 
diabetic rats displayed a highly significant increase 
in the levels of serum alkaline phosphatase and os-
teocalcin. Alkaline phosphatase is an enzyme marker 
Figure 5. A–E. Photomicrographs of different sections of the distal femur diaphysis from diabetic rats treated with both insulin and parathy-
roid hormone showing increased thickness of the outer cortical bone (CB) to be comparable with the controls with the appearance of sub- 
periosteal bone deposition with a distinct basophilic cement line (arrow). The cortical bone (CB) showed concentric bone lamellae (Cl) around 
apparently normal Haversian canals (HC). Notice the presence of many osteocytes (Os) inside their lacunae. The periosteum (Pr) shows 
increase in the thickness of its outer fibrous and inner osteogenic layers. The spongy bone appears with normal trabeculae (T) with less ap-
parent widening in the interconnecting bone marrow spaces. The trabeculae presented with distinct deep basophilic cement lines and areas; 
BM — bone marrow; En — endosteum; haematoxylin and eosin; × 100: A, E; × 200: B, C; × 600: D. 
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of osteoblasts. It was used as a marker for bone 
formation due to its role in bone mineralisation and 
matrix production [58]. The impaired differentiation 
and maturation of osteoblasts in DM resulting in de-
creased bone formation can be traced by the decrease 
of serum osteocalcin levels as well as reduced mRNA 
levels of osteocalcin [8, 17]. 
In the present study, the untreated diabetic rats 
have displayed a decreased femoral length, weight 
and cortical thickness. Several studies examining 
physical properties of diabetic bone showed that 
hindrance of bone growth and healing is associated 
with a decreased mechanical strength of bone and 
not in bone production [18]. Interestingly, Reddy et 
al. [43] found that the strength-related properties 
are reduced in DM. These changes might be related 
to possible injurious effects of DM on bone miner-
alisation. However, it has been agreed that that me-
chanical and physical properties are not affected by 
DM. Moreover, insulin treatment can improve bone 
breaking strengths, which suggests that deficiency 
of bone is an effect associated with DM [23]. 
The diabetic rats in the present study, revealed 
marked thinning of the cortical bone and bone 
trabeculae with their wide separation and areas of 
osteolysis, which appeared as faint staining with 
absence of osteocyte lacunae. Also, multiple erosion 
cavities were frequently seen in the endosteal surface 
of cortical bone and spongy bone in the diabetic 
rats. It was reported that osteoporosis is manifested 
in the trabeculae of spongy bone as thinning, total 
removal or combination of thinning and total loss. 
This might be associated with residual trabeculae of 
normal thickness [50]. Similarly, Devesh et al. [13] 
reported that the histopathology results of diabetic 
rats showed destruction of medullary cavity at the 
expense of the bone tissue thickness and gaps for-
mation in Haversian canals within the bone tissue. 
In the present study, degeneration of osteoblasts 
and osteocytes, lacunae devoid of cells, multiple 
erosion cavities; decreased collagen fibres and ir-
regular bone surface were observed. In accordance 
with these observations, it was reported that bone 
turnover was depressed as evidenced by a decrease 
in the number of osteoblasts and in osteocalcin 
synthesis as well as inhibition of osteoblastic activi-
ties and proliferation [32]. Inhibition of osteoblast 
might be due to absence of the anabolic effects of 
insulin [22], decreased production of growth fac-
tors that regulate osteoblast differentiation [21], 
and apoptosis of osteoblast [44]. Moreover, osteo-
poenia in DM could result from hindering of bone 
matrix [45]. Also, it was reported that insulin plays 
a significant role in bone health in DM [54]. 
In the present study, insulin treatment of the dia-
betic rats resulted in relative improvement in BMD, 
biochemical and morphometric parameters as well as 
the bone osteoporotic changes, in accordance with 
these observations, it was reported that controlled 
insulin therapy may reverse the impairment in fracture 
repair in diabetic patients with poor metabolic cont- 
rol [7]. Also, localised insulin therapy improved frac-
ture healing in diabetic animal models via chondro-
genesis and cellular proliferation [19]. 
The results of the present study demonstrated 
more favourable effect of PTH treatment of diabetic 
rats on the BMD, biochemical and morphometric re-
sults as well as the histological appearance of bone 
tissue. Similarly, it was reported that PTH therapy 
of STZ-diabetic rats also enhances bone formation 
markers and bone density [34]. Furthermore, peri-
osteal activity was noticed as indicated by the ap-
parently increased thickness of the inner osteogenic 
layer of the periosteum, which contained abundant 
osteoblasts. Many investigators found abundant 
basophilic osteoblasts in the active periosteum 
[62]. Also, it was mentioned that periosteal bone 
formation could be a compensatory mechanism to 
keep bone strength in case of bone loss resulting 
from trabecular and endocortical surfaces [12]. 
The mechanism of PTH action in bone depends 
on its dose. The dose of PTH (6.0 μg/kg/day) in the 
present study was more clinically relevant com-
pared with previous studies using higher doses 
in animal models [14, 36]. Chronic elevation of 
serum PTH level causes net bone resorption and 
calcium release [29]. However, intermittent PTH 
treatment causes a net increase in bone formation 
and reduction of fracture risk [5]. Several previous 
studies have shown that insulin-like growth factor 
1 modulates the anabolic effects of PTH on osteo-
blasts or bone [38]. These findings suggest that 
the PTH signalling pathway may interact with an 
insulin-like growth factor 1 signalling pathway at 
one or more points. 
In the present study, the combined treatment 
with both insulin and PTH of the experimental-
ly induced diabetic rats has nearly reversed the 
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osteoporotic changes to the normal architecture 
and produced best results regarding morphomet-
ric, biochemical and BMD in comparison with the 
control rats. Moreover, the histological evaluation 
showed that combined insulin and PTH treatment 
had a greater anabolic effect and retained almost 
normal structure of the cortical and spongy bones 
than treatment with PTH or insulin alone by increas-
ing the bone formation considerably. Although PTH 
and insulin are expected to have anabolic effects on 
diabetic rats, the present study demonstrated that 
PTH or insulin alone is less effective than a combina-
tion of these agents. 
Because of PTH therapeutic ability to restore bone 
density to normal levels after bone loss, it might be 
an option to promote the depressed bone formation 
and resorption in diabetic patients. The long-term 
safety and mechanisms of PTH action on diseased 
bone and its repair is a future question that needs 
to be addressed in clinical studies [40]. 
CONCLUSIONS
It was clearly observed that untreated DM in 
diabetic group resulted in a dramatic reduction in 
BMD, morphometric and biochemical parameters. 
Treatment with insulin ameliorated these effects to 
some extent, while PTH co-treatment had a more 
positive effect than insulin. The combination of PTH 
and insulin as a treatment of DM resulted in more 
improvement of all parameters to approximately like 
that of control rats, which mean that PTH had a syn-
ergetic effect with insulin in the amelioration of the 
osteoporotic effects of experimental DM. 
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